Despite major recent advances in oncology drug discovery, including the development of innovative targeted, immune and cell-based therapies, there remain many opportunities to improve outcomes for patients with cancer. Some may not benefit from available treatments, and others may have highly aggressive or drug-resistant cancers that require new options.
As part of MD Anderson’s commitment to bring our patients the most effective...
Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...
Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...
Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2 mutations in lung cancer, researchers at MD Anderson have now characterized HER2 mutation type and frequency across cancer types and found that poziotinib shows activity against the most common HER2 variants seen in cancer.
The study also reports results from a phase II clinical trial, in which...
